- Home
- ALXO vs FGF Comparison
ALXO vs FGF Comparison
Compare ALXO & FGF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- FGF
- Stock Information
- Founded
- ALXO 2015
- FGF 2012
- Country
- ALXO United States
- FGF United States
- Employees
- ALXO N/A
- FGF N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- FGF Property-Casualty Insurers
- Sector
- ALXO Health Care
- FGF Finance
- Exchange
- ALXO Nasdaq
- FGF Nasdaq
- Market Cap
- ALXO 24.0M
- FGF 20.9M
- IPO Year
- ALXO 2020
- FGF N/A
- Fundamental
- Price
- ALXO $0.61
- FGF $18.86
- Analyst Decision
- ALXO Strong Buy
- FGF
- Analyst Count
- ALXO 6
- FGF 0
- Target Price
- ALXO $3.30
- FGF N/A
- AVG Volume (30 Days)
- ALXO 500.5K
- FGF 19.7K
- Earning Date
- ALXO 08-07-2025
- FGF 08-13-2025
- Dividend Yield
- ALXO N/A
- FGF N/A
- EPS Growth
- ALXO N/A
- FGF N/A
- EPS
- ALXO N/A
- FGF N/A
- Revenue
- ALXO N/A
- FGF $13,260,000.00
- Revenue This Year
- ALXO N/A
- FGF N/A
- Revenue Next Year
- ALXO N/A
- FGF N/A
- P/E Ratio
- ALXO N/A
- FGF N/A
- Revenue Growth
- ALXO N/A
- FGF N/A
- 52 Week Low
- ALXO $0.40
- FGF $14.21
- 52 Week High
- ALXO $6.08
- FGF $38.40
- Technical
- Relative Strength Index (RSI)
- ALXO 61.99
- FGF 56.80
- Support Level
- ALXO $0.44
- FGF $19.43
- Resistance Level
- ALXO $0.64
- FGF $27.97
- Average True Range (ATR)
- ALXO 0.04
- FGF 2.42
- MACD
- ALXO 0.01
- FGF 0.26
- Stochastic Oscillator
- ALXO 72.40
- FGF 40.74
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.